Discover PANGAEA’s world
Our PhDs participate in scientific publications in peer-reviewed journals
Our latest news, events, meetings, announcements and stories
OUR LATEST SCIENTIFIC PUBLICATIONS
- Rafael Rosell & Peng Cao
“Promising outlook with sugemalimab in non-small-cell lung cancer”
Lancet Oncology 2022 Published Online January 14, (Vol 23): 186-187, 2022. IF: 41.316.
- Rafael Rosell, Maria González-Cao
“Ablating lung cancer, knowing the tumor better” The Lancet Regional Health – Europe 2022;22: 100494.
- Rafael Rosell, Andrés F. Cardona, Oscar Arrieta, María González-Cao
“Classification of atypical EGFR mutations in non-small-cell lung cancer” Ann Oncol 2022 Mar 21;S0923-7534(22)00389-1. Vol 33, Issue 6, P571-573, June 01, 2022 IF: 51.769.
- AF Cardona, M González-Cao, O Arrieta & Rafael Rosell.
“Location of EGFR exon 20 insertions matters” Cancer Cell 2022. IF: 31.743.
- M González-Cao et al.
“COVID-19 in Melanoma Patients: Results of the Spanish Melanoma Group Registry, GRAVID study”
Journal of the American Academy of Dermatology 2021, 84 (5): 1412-1415. IF: 8.277.
- Rosell R, Cardona AF.
“Poziotinib treatment in intractable NSCLC: EGFR and HER2 exon 20 insertion mutation disease” European Journal of Cancer, 2021. IF: 7.275.
- Rosell R, González-Cao M.
“Cemiplimab monotherapy in advanced non-squamous and squamous NSCLC” Lancet 2021. Vol 397 February 13: 557-559. IF: 60.392.
- Bracht, J.W.P., Gimenez-Capitan, A., Huang, CY. et al.
“Analysis of extracellular vesicle mRNA derived from plasma using the nCounter platform” Sci Rep 11, 3712 (2021). IF: 3.99.
- Rosell R, Ito M.
“Neoadjuvant atezolizumab plus chemotherapy in resectable
non-small-cell lung cancer”
Lancet Oncology, 2020 Jun;21(6):736-738. IF: 35. 386.
- Rosell R, Cardona AF.
“Poziotinib treatment in intractable NSCLC: EGFR and HER2 exon 20 insertion mutation disease” European Journal of Cancer, 2021. IF: 7.275.
- Maria González-Cao; Javier Martinez-Picado; Rafael Rosell.
“Safety of anti-PD-L1 inhibition in HIV-1-infected cancer patients” (Response letter of A. Dekker). JAMA Oncology 2020. (Accepted). IF: 22.416.
- Rafael Rosell, Imane Chaib, Mariacarmela Santarpia.
“Targeting MET amplification in EGFR-mutant non-small-cell lung cancer” Lancet Respir Med. 2020 Published online May 22, 2020. IF: 15.780.
- Karachaliou N, Fernandez Bruno M, Bracht JWP, Rafael Rosell.
“Profile of alectinib for the treatment of ALK-positive Non-Small Cell Lung Cancer (NSCLC): patient selection and perspectives” OncoTargets and Therapy 2019. IF: 2.656.
- Niki Karachaliou, Manuel Fernandez-Bruno, Jillian Wilhelmina Paulina Bracht, Rafael Rosell.
“EGFR first- and second-generation TKIs—there is still place for them in EGFR-mutant NSCLC patients” Transl Cancer Res 2019; 8 (Suppl 1): S23-S47 IF: 1.2.
- Jillian Wilhelmina Paulina Bracht, Niki Karachaliou, Jordi Berenguer, Manuel Fernandez-Bruno, Martyna Filipska, Carlos Pedraz-Valdunciel, Carles Codony-Servat, Jordi Codony-Servat, Rafael Rosell.
“PIM-1 inhibition with AZD1208 to prevent osimertinibinduced resistance in EGFR-mutation positive non-small cell lung cancer.” Journal of Cancer Metastasis and Treatment 2019.
- Andrés F. Cardona, Alejandro Ruiz-Patiño, Luisa Ricaurte, Leonardo Rojas, Zyanya Lucia Zatarain-Barrón, Oscar Arrieta, Rafael Rosell.
“Human Papillomavirus Infection and Lung Cancer Current Perspectives in Human Papillomavirus” (BOOK CHAPTER)
IntechOpen, 2019.
- Irene Moya-Horno, Santiago Viteri, Rafael Rosell
“Unsuspected N2-positive non-small cell lung cancer after complete resection: is there a place for multimodal adjuvant therapy?” AME Medical Journal. February 2018.
- Niki Karachaliou, Imane Chaib, Andres Felipe Cardona, Jordi Berenguer, Jillian Wilhelmina Paulina Bracht, Jie Yang, et al.
“Common Co-activation of AXL and CDCP1 in EGFR-mutation-positive Non-small cell Lung Cancer Associated With Poor Prognosis” EBioMedicine, February 2018, Epub ahead of print.
- Karachaliou N, Gonzalez-Cao M, Crespo G, et al.
“Interferon gamma, an important marker of response to immune checkpoint blockade in non-small cell lung cancer and melanoma patients” AME Medical Journal. Therapeutic Advances in Medical Oncology, January 18, 2018.
- Irene Moya-Horno, Santiago Viteri, Niki Karachaliou, Rafael Rosell
“Combination of immunotherapy with targeted therapies in advanced non-small cell lung cancer (NSCLC)” Therapeutic Advances in Medical Oncology, January 9, 2018.
Discover our latest news
- All Post
- Instituto Oncológico Rosell
- Pangaea Oncology
- Quénet Torrent Institute
Pangaea Oncology boosts growth through small acquisitions in private healthcare. Take advantage of more personalized and less toxic drugs based on the genetic profiles of each patient.
We are pleased to share the success story of Anisha Jain, a PhD student from the JSS Medical Research, India. Thanks to EACR Travel Fellowship, join us at Instituto Oncológico Dr. Rosell.
The decision whether or not to add HIPEC to surgery in ovarian cancer recurrence is clear: intraoperative chemotherapy increases survival without added toxicity.